What type of derivative security did Mittie Doyle exercise related to AVTX?

Mittie Doyle exercised a Stock Option (Right to Buy) covering 1,000 shares of Avalo Therapeutics common stock at an exercise price of $12.65 per share, with the option originally scheduled to expire on July 15, 2034.

Avalo CMO sells 1,000 shares after option exercise

Q: What insider transaction did AVTX Chief Medical Officer Mittie Doyle report on this Form 4?

Mittie Doyle reported exercising 1,000 stock options at $12.65 and selling 1,000 common shares at $20.00 on August 17, 2026. The option exercise and share sale were reported as separate transactions on the same date.

Q: How many AVTX shares does Mittie Doyle hold after the reported transactions?

After the option exercise, Mittie Doyle directly owned 123,750 shares of Avalo Therapeutics common stock. This post-transaction holding reflects the Form 4’s reported total shares following the derivative transaction entry.

Q: At what prices did Mittie Doyle exercise and sell AVTX shares?

Mittie Doyle exercised stock options to buy 1,000 shares at $12.65 per share and then sold 1,000 shares at $20.00 per share. Both transactions occurred on August 17, 2026, as disclosed in the filing.

Avalo Therapeutics, Inc. (AVTX) reported insider transactions by Chief Medical Officer Mittie Doyle.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Avalo Therapeutics, Inc. (AVTX) reported insider transactions by Chief Medical Officer Mittie Doyle. On August 17, 2026, Doyle exercised options to acquire 1,000 shares of common stock at $12.65 per share and sold 1,000 shares at $20.00 per share, pursuant to a Rule 10b5-1 trading plan adopted on November 13, 2025. Following the option exercise, Doyle directly owned 123,750 shares of common stock.

Insider Trade Summary 10b5-1

Exercise and Sale: 1,000 shares ($7K approx. pre-tax spread)

Exercise and Sale 3 txns

Insider Doyle Mittie

Role Chief Medical Officer

Sold 1,000 shs ($20K)

Approx. gross sale proceeds $20K

Approx. exercise cost $13K

Approx. pre-tax spread $7K

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy) ^{F1, F2}	1,000	$0.00	$0.00
Exercise	Common Stock ^F1	1,000	$12.65	$13K
Sale	Common Stock ^F1	1,000	$20.00	$20K

Holdings After Transaction: Stock Option (Right to Buy) — 123,750 contracts (Direct); Common Stock — 51,776 shares (Direct)

Footnotes (2)

F1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025.
F2. The stock option vests twenty-five percent (25%) on July 15, 2025 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on each such vesting date.

Key Figures

Options Exercised: 1,000 shares Option Exercise Price: $12.65 per share Shares Sold: 1,000 shares +4 more

7 metrics

Options Exercised 1,000 shares Stock Option (Right to Buy) exercised on August 17, 2026

Option Exercise Price $12.65 per share Exercise price for 1,000-stock-option derivative security

Shares Sold 1,000 shares Common Stock sale on August 17, 2026

Sale Price $20.00 per share Per-share price for 1,000 common shares sold

Post-transaction Holdings 123,750 shares Directly owned common shares after option exercise

Option Expiration Date July 15, 2034 Expiration date of the exercised stock option

10b5-1 Plan Adoption Date November 13, 2025 Date Mittie Doyle adopted Rule 10b5-1 trading plan

Key Terms

Rule 10b5-1 trading plan, Stock Option (Right to Buy), Exercise or conversion of derivative security, Common Stock

4 terms

Rule 10b5-1 trading plan regulatory

"The transactions reported ... were effected pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

Exercise or conversion of derivative security financial

"transaction_code_description: Exercise or conversion of derivative security"

Common Stock financial

"underlying_security_title: Common Stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did AVTX Chief Medical Officer Mittie Doyle report on this Form 4?

Mittie Doyle reported exercising 1,000 stock options at $12.65 and selling 1,000 common shares at $20.00 on August 17, 2026. The option exercise and share sale were reported as separate transactions on the same date.

How many AVTX shares does Mittie Doyle hold after the reported transactions?

After the option exercise, Mittie Doyle directly owned 123,750 shares of Avalo Therapeutics common stock. This post-transaction holding reflects the Form 4’s reported total shares following the derivative transaction entry.

At what prices did Mittie Doyle exercise and sell AVTX shares?

Mittie Doyle exercised stock options to buy 1,000 shares at $12.65 per share and then sold 1,000 shares at $20.00 per share. Both transactions occurred on August 17, 2026, as disclosed in the filing.

Was Mittie Doyle’s AVTX trading done under a Rule 10b5-1 plan?

Yes. The Form 4 states that all reported transactions were effected under a Rule 10b5-1 trading plan adopted by Mittie Doyle on November 13, 2025, indicating the trades were pre-arranged under that plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 08/19/2026 - 04:11 PM Accepted by SEC EDGAR 08/19/2026 - 04:10 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Doyle Mittie

(Last)

(First)

(Middle)

C/O AVALO THERAPEUTICS, INC.

1500 LIBERTY RIDGE DRIVE, SUITE 321

(Street)

WAYNE

PENNSYLVANIA

19087

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Avalo Therapeutics, Inc. [ AVTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	08/17/2026		M⁽¹⁾		1,000	A	$12.65	52,776	D
Common Stock	08/17/2026		S⁽¹⁾		1,000	D	$20	51,776	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$12.65	08/17/2026		M⁽¹⁾			1,000	⁽²⁾	07/15/2034	Common Stock	1,000	$0	123,750	D

Explanation of Responses:

1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025.

2. The stock option vests twenty-five percent (25%) on July 15, 2025 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on each such vesting date.

	/s/ Christopher Sullivan, Attorney-in-Fact	08/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR